UTI antibiotics Rx-to-OTC switch would not be cost effective -- epidemiology study.
This article was originally published in The Tan Sheet
Executive Summary
UTI ANTIBIOTICS Rx-TO-OTC SWITCH WOULD NOT BE COST-EFFECTIVE in the long term, Betsy Foxman, PhD, University of Michigan School of Public Health, and Nicole Rubin of the Sausalito, Calif.-based Lewin Group, assert in the November Journal of Clinical Epidemiology. OTC sale of antibiotics for urinary tract infections would lead to additional treatment costs of "more than $300 mil." over a 20-year period as well as increased resistance to the drugs resulting from their expanded availability, according the authors' cost-effectiveness analysis conducted under a grant from the National Institute of Diabetes & Digestive & Kidney Diseases.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning